BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?

BioNTech (NasdaqGS:BNTX) just expanded its oncology pipeline by announcing new Phase 2 data for pumitamig plus docetaxel in metastatic non small cell lung cancer, alongside a new Phase 3 collaboration in triple negative breast cancer. Despite a steady flow of oncology updates in October, BioNTech’s share price has moved unevenly, with a 7-day share price return of 0.46% sitting against a 30-day decline of 10.56% and a 1-year total shareholder return decline of 16.61%. This combination points...